



November 7, 2022

Alina Garbar, RA Director
Aurora Pharmaceutical, Inc.
1196 Hwy. 3 South
Northfield, MN 55057

Sent via email to: agarbar@aurorapharmaceutical.com

Dear Petitioner:

Your submission requesting an FDA permission to submit an abbreviated new animal drug application (ANADA) for a generic meloxicam oral solution (1.5 mg/mL and 0.5 mg/mL strengths) for use in dogs that differs from reference listed new animal drug (RLNAD) in dosage form was received and processed under CFR 10.30 by this office on 11/04/2022.

It was assigned docket number FDA-2022-P-2795. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note, the acceptance of the suitability petition for filing is a procedural matter and in no way reflects the Agency's decision on the substantive merits of the petition.

Sincerely,

Karen Malvin
Acting Director
Dockets Management Staff
FDA/Office of Operations (OO)